All patients total | Total | Dead at 1 year | Survived at 1 year | Dead at the end of the study | Survival at the end of study | P value |
Number of patients | 6713 (100%) | 870 (13.0) | 5830 (87.0%) | 2066 (30.8%) | 4634 (69.2%) | |
Age, years, (median, IQR) | 83 (81–85) | 84 (82–87) | 83 (81–85) | 84 (81–87) | 83 (81–85) | <0.001* |
Female sex | 2968 (44.2) | 367 (12.4) | 2598 (87.6) | 847 (28.6) | 2118 (71.4) | <0.001‡ |
BMI (mean, SD) | 26.0 (4.7) | 25.4 (4.2) | 26.0 (4.7) | 25.7 (4.2) | 26.1 (4.9) | <0.001† |
Hb (mean, SD) | 132.1 (16.0) | 126.6 (17.3) | 132.9 (15.6) | 128.0 (16.8) | 133.9 (15.3) | <0.001† |
CRP, median (IQR) | 5 (2.3–12) | 9 (4–31) | 5 (2–10) | 6.4 (3.9–23) | 5 (2–9) | <0.001* |
LDL (mean, SD) | 2.8 (1.1) | 2.6 (1.1) | 2.8 (1.1) | 2.6 (1.0) | 2.9 (1.1) | <0.001† |
eGFR (mL/min/1.73 m2) | <0.001‡ | |||||
>60 | 3527 (55.8) | 326 (9.3) | 3199 (90.7) | 852 (24.2) | 2668 (75.8) | |
60–30 | 2465 (39.0) | 375 (15.2) | 2088 (84.6) | 890 (36.2) | 1570 (63.8) | |
30–15 | 329 (5.2) | 101 (30.7) | 228 (69.1) | 184 (55.9) | 145 (44.1) | |
Prior MI | 2732 (40.7) | 425 (15.6) | 2302 (84.4) | 1059 (38.9) | 1668 (61.2) | <0.001‡ |
Heart failure | 994 (15.6) | 213 (21.5) | 780 (78.6) | 466 (47.0) | 527 (53.1) | <0.001‡ |
Prior stroke | 738 (11.0) | 133 (18.1) | 604 (82.0) | 295 (40.0) | 442 (60.0) | <0.001‡ |
Prior revascularisation: PCI | 1611 (24.0) | 187 (11.6) | 1420 (88.4) | 550 (34.2) | 1057 (65.8) | <0.01‡ |
CABG | 321 (4.8) | 34 (10.7) | 285 (89.3) | 81 (25.4) | 238 (74.6) | 0.03‡ |
Hypertension | 4226 (63.0) | 568 (13.5) | 3650 (86.5) | 1330 (31.5) | 2888 (68.5) | 0.24‡ |
Diabetes | 1654 (24.6) | 276 (16.7) | 1375 (83.3) | 654 (39.6) | 997 (60.4) | <0.001‡ |
LVEF | <0.001‡ | |||||
≥50% | 2772 (55.5) | 197 (7.1) | 2569 (92.9) | 571 (20.6) | 2195 (79.4) | |
40%–50% | 1104 (22.1) | 146 (13.2) | 957 (86.8) | 350 (31.7) | 753 (68.3) | |
30%–39% | 729 (14.6) | 136 (18.7) | 590 (81.3) | 276 (38.0) | 450 (62.0) | |
<30% | 338 (6.8) | 116 (34.3) | 222 (65.7) | 200 (59.2) | 138 (40.8) | |
Unknown | 51 (1.0) | 7 (13.7) | 44 (86.3) | 14 (27.5) | 37 (72.6) | |
Medications | ||||||
Aspirin | 5990 (89.2) | 694 (11.6) | 5283 (88.4) | 1753 (29.3) | 4224 (70.7) | <0.001‡ |
P2Y12 inhibitors | 5472 (81.2) | 597 (10.9) | 4864 (89.1) | 1560 (28.6) | 3901 (71.4) | <0.001‡ |
Betablockers | 5776 (86.2) | 665 (11.5) | 5103 (88.5) | 1710 (29.7) | 4058 (70.4) | <0.001‡ |
ACEi/ARB | 3583 (53.5) | 382 (10.7) | 3196 (89.3) | 1032 (28.8) | 2546 (71.2) | <0.001‡ |
Statin | 5703 (85.0) | 581 (10.2) | 5111 (89.8) | 1575 (27.7) | 4117 (72.3) | <0.001‡ |
Antikoagulantia | 986 (14.7) | 111 (11.3) | 875 (88.7) | 310 (31.4) | 676 (68.6) | 0.62‡ |
P value indicate overall survival comparing between treatments.
Data are number of patients and percentages, unless otherwise noted.
*T-test.
†Mann-Whitney test.
‡χ2 test.
ACEi, ACE inhibitor; ARB, angiotensin II receptor antagonists; BMI, body mass index; BMS, bare metal stent; CABG, coronary artery bypass graft; CRP, C reactive protein; DES, drug eluting stent; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.